4 completed, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Mixed Oligoastrocytoma: new trials by email Literature Review of Mixed Oligoastrocytoma trials Research Report on Mixed Oligoastrocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors MRI-guided laser ablation, Doxorubicin, Etoposide - Glioma, Pilocytic Astrocytoma | Phase 2 | Terminated | Washington University School of Medicine | 6 | 2015-08-14 | 2024-11-01 |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma IL13-PE38QQR, targeted fusion protein therapy, surgery - Malignant Glioma, Glioblastoma Multiforme | Phase 1 | Completed | INSYS Therapeutics Inc | 18 | 2003-07-01 | 2011-06-06 |
| Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma IL13-PE38QQR, targeted fusion protein therapy, surgery - Malignant Glioma, Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | INSYS Therapeutics Inc | 80 | 2002-07-01 | 2011-06-06 |
| Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients IL13-PE38QQR, targeted fusion protein therapy, surgery - Malignant Glioma, Glioblastoma Multiforme | Phase 1 | Completed | INSYS Therapeutics Inc | 40 | 2001-06-01 | 2011-06-06 |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma IL13-PE38QQR, targeted fusion protein therapy, surgery - Malignant Glioma, Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | INSYS Therapeutics Inc | 60 | 2000-11-01 | 2014-11-14 |
Astrocytoma (5) · Glioblastoma (5) · Glioma (5) · Oligodendroglioma (2) · Recurrence (2) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Optic Nerve Glioma (1)
Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Neoplasms (4) · Disease Attributes (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1)
IL13-PE38 (4) · Surgical Procedures, Operative (4) · Doxorubicin (1) · Dynamic Contrast Enhanced Magnetic Resonance Imaging (1) · Etoposide (1) · Perfusion Magnetic Resonance Imaging (1) · etoposide phosphate (1)
INSYS Therapeutics Inc (4) · Washington University School of Medicine (1)
United States (5) · Germany (1) · Israel (1)
Andrew Cluster, M.D. (1) · Jon Weingart, MD (1)